Skip to main content
/ IR Insights: Recapping our Fourth Quar...
22 February 2024

IR Insights: Recapping our Fourth Quarter and Fiscal Year 2023 Earnings Report

by Moderna
IR Insights Q4 2023

Earlier today, Moderna reported financial results and provided business updates for the fourth quarter and fiscal year 2023. We provided the investor community with an update on our business and clinical updates across infectious disease, oncology and rare disease.

Members of our executive team sat down to provide more insight into our financial performance, key milestones, and the exciting clinical and corporate developments happening at Moderna. Watch our latest IR Insights video below to hear more from our CEO Stéphane Bancel and CFO Jamey Mock:

Stay tuned for more updates and follow us on LinkedIn and Twitter to learn more about Moderna and how we’re changing the future of medicine.

Forward-Looking Statements

This post and accompanying video contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding:  Moderna's anticipated approval and launch of its RSV vaccine in 2024 and 2025, market dynamics, and its competitive profile; Moderna's 2024 financial framework and anticipated performance, including expected revenues; the potential for Moderna to launch up to 15 products in the next five years; anticipated milestones for Moderna's pipeline programs in 2024; and the future profitability of Moderna's COVID-19 vaccine franchise. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “could,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this post are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading “Risk Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this post in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date of this post.